Four companies are set to raise a combined $270 million in the week ahead. Most notable deal Medpace, a contract research organization focused on biotechs, is joined by two potential customers: Protagonist Therapeutics and Motif Bio. Thanks to insider support, biotechs are the most active segment of the 2016 IPO market, with 20 offerings year-to-date (36% of total), but their average return (-2%) far underperforms the year's non-biotechs (+26%). This may be the last week of significant activity before the yearly summer slowdown, with activity likely picking up again after Labor Day.
Medpace Holdings (MEDP) is a global full-service CRO focused on small and mid-sized biopharmas. Set to raise $151 million on a market cap of $863 million, its industry-leading EBITDA margins and strong free cash flow generation is a potential draw for investors. By focusing on the faster-growing portion of the $23 billion Phase I-IV CRO market, Medpace has been able to grow revenue at a 22% CAGR from 2012-2015. CRO peer inVentiv (INV) withdrew its IPO plans early in the month after receiving a significant equity investment. Overall, Medpace's peers have been doing well, with both PRA Health Science (PRAH) and INC Research (INCR) trading up well over 100% since their respective 2014 IPOs.
Protagonist Therapeutics (PTGX) is slated to raise $70 million at a market cap of $190 million. Focusing on ulcerative colitis and Crohn’s disease, the biotech’s lead candidate completed Phase 1 trials and is scheduled to enter Phase 2b trials in the 4Q16. A second candidate is expected to begin Phase 1 trials in 2017. Though its administration (oral as opposed to injectable) is novel, the drug would enter a crowded field led by AbbVie’s blockbuster Humira.
Motif Bio (MTFB) is a late stage biotech focused on antibiotics for multi-drug resistant bacteria. The company, which is currently listed on London’s AIM market, hopes to raise $35 million at a market cap of $110 million. Lead candidate, Iclaprim, which previously failed to receive FDA approval, was acquired in 2015 and is currently in two Phase 3 trials.
Airgain (AIRG), which supplies embedded antenna components to enable wireless networking in electronic devices, is set to raise $14 million at a market cap of $78 million. The company hopes to cash in on the growing IoT industry as it battles falling ASPs.
|
Renaissance Capital's IPO Calendar - Week of 8/8/2016 |
||||
|
Issuer |
Symbol |
Deal Size |
Price Range |
Lead Manager(s) |
|
Medpace Holdings |
MEDP |
$151 |
$20 - $23 |
Jefferies |
|
Global CRO focused on small and mid-sized biopharmaceuticals. |
||||
|
Protagonist Therapeutics |
PTGX |
$70 |
$11 - $13 |
Leerink Partners |
|
Developing peptide-based oral drugs for inflammatory bowel disease. |
||||
|
Motif Bio |
MTFB |
$35 |
$12.42 |
SunTrust Robinson Humphrey |
|
Late-stage biotech developing antibiotics for multi-drug resistant bacteria. |
||||
|
Airgain |
AIRG |
$14 |
$9 - $10 |
Northland Securities |
|
Supplies embedded antennas for Wi-Fi routers and other electronic devices. |
||||
Follow us on Twitter (@IPOtweet) for IPO news as it happens and register for our updates on the IPO market.
IPO Market Snapshot
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. The Renaissance IPO Index is down 3% year-to-date, while the S&P 500 is up 7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Alibaba (BABA), Synchrony Financial (SYF) and Citizens Financial Group (CFG). The Renaissance International IPO Index is down 4% year-to-date, compared to +4% for ACWX. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include NN Group and Aena S.A. To find out if this is the best ETF for you, visit our IPO Investing page.
